Cancers | Free Full-Text | Denosumab in Giant Cell Tumor of Bone: Multidisciplinary Medical Management Based on Pathophysiological Mechanisms and Real-World Evidence
Long-term follow up after denosumab treatment for osteoporosis – rebound associated with hypercalcemia, parathyroid hyperplasia, severe bone mineral density loss, and multiple fractures: a case report | Journal of Medical Case Reports
Prolia® (denosumab) DAPS Study Design | Prolia®
Prolia® (denosumab) DAPS Study Design | Prolia®
New and emerging concepts in the use of denosumab for the treatment of osteoporosis - E. Michael Lewiecki, 2018
Long-term consequences of osteoporosis therapy with denosumab - Archives of Endocrinology and Metabolism
Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab | Nature Reviews Drug Discovery
DB06643 Denosumab C6404H9912N1724O2004S kDa CATEGORY - ppt download
Greater BMD rise with denosumab than ibandronate as sequential treatment to romosozumab
Denosumab – die reversible Wirksamkeit im klinischen Fokus Denosumab – the reversible efficacy in the clinical focus
Effects of denosumab followed by zoledronate on BMD in postmenopausal... | Download Scientific Diagram
Treatment Sequences with Romosozumab Before or After Antiresorptive Medication - ACR Meeting Abstracts
Frontiers | Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy
Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study - The Lancet Oncology
Frontiers | Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials
Prolia, INN-denosumab
JCM | Free Full-Text | Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone | Nature Reviews Rheumatology
FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab - Cosman - 2018 - Journal of Bone and
When to Start Prolia® After EVENITY®
When to Start Prolia® After EVENITY®
Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab | SpringerLink
WO2013181575A2 - Methods related to denosumab - Google Patents
Romosozumab and antiresorptive treatment: the importance of treatment sequence | SpringerLink
Figures and data in Modeling osteoporosis to design and optimize pharmacological therapies comprising multiple drug types | eLife
Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL | Oncotarget
